AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6951838 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine evening rinse
Number of subjects: 18
Study 6951838 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine morning rinse
Number of subjects: 18
Study 30282096 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicortical tibial fixation
Number of subjects: 8
Study 30282096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicortical tibial fixation
Number of subjects: 8
Study 30282096 — intervention group
Group type: COMPARATOR
Intervention: PCL-deficient knees
Number of subjects: 8
Study 30282096 — intervention group
Group type: COMPARATOR
Intervention: PCL-intact knees
Number of subjects: 8
Study 30336824 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly
Number of subjects: 968
Study 30336824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 26749079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation
Number of subjects: 43
Study 26749079 — intervention group
Group type: COMPARATOR
Intervention: Ahmed glaucoma valve implantation alone
Number of subjects: 43
Study 26749079 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 23139071 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy using LED light (Fotosan) with toluidine blue O solution
Number of subjects: 30
Study 23139071 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (control)
Number of subjects: 30
Study 22197412 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan toothpaste
Number of subjects: 132
Study 22197412 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 132
Study 17556431 — intervention group
Group type: COMPARATOR
Intervention: SSRI and routine care
Number of subjects: 208
Study 17556431 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI, routine care, and CBT
Number of subjects: 208
Study 15134608 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) using the Dornier Epos Ultra, single therapy session
Number of subjects: 150
Study 15134608 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Control Group)
Number of subjects: 150
Study 11586670 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (ACE inhibitor)
Number of subjects: 0
Study 11586670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9532417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound (90 dB, 1 kHz for 30s)
Number of subjects: 90
Study 9532417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 90
Study 8083130 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (7 Gy single fraction administered < 4 h before surgery)
Number of subjects: 84
Study 8083130 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy (5 fractions of 3.5 Gy, total dose 17.5 Gy administered < 72 h after surgery)
Number of subjects: 84
Study 8083130 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 84
Study 8083130 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 84
Study 2511802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 7 days
Number of subjects: 79
Study 2511802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 600 mg once daily for 7 days
Number of subjects: 79
Study 2511802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 800 mg once daily for 7 days
Number of subjects: 79
Study 2511802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (600 or 800 mg) once daily for 7 days
Number of subjects: 79
Study 2511802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 79
Study 765518 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours)
Number of subjects: 28
Study 765518 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (100 mg/kg/day administered in divided doses every six hours)
Number of subjects: 28
Study 765518 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 28
Study 31284617 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) algorithm for LST retrieval from AMSR2 data
Number of subjects: 0
Study 31284617 — intervention group
Group type: COMPARATOR
Intervention: Comparison with ground measurement data from meteorological stations
Number of subjects: 0
Study 28433454 — intervention group
Group type: EXPERIMENTAL
Intervention: nTTT
Number of subjects: 42
Study 28433454 — intervention group
Group type: COMPARATOR
Intervention: TFT
Number of subjects: 42
Study 28433454 — intervention group
Group type: COMPARATOR
Intervention: TTHT
Number of subjects: 42
Study 24528807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) 220kcal
Number of subjects: 188
Study 24528807 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn-soy blend (CSB) 284kcal
Number of subjects: 188
Study 24528807 — intervention group
Group type: COMPARATOR
Intervention: No supplements (control)
Number of subjects: 188
Study 22845008 — intervention group
Group type: EXPERIMENTAL
Intervention: BAF312 dose titration regimen DT1 (0.25-10 mg over 9-10 days)
Number of subjects: 56
Study 22845008 — intervention group
Group type: EXPERIMENTAL
Intervention: BAF312 dose titration regimen DT2 (0.25-10 mg over 9-10 days)
Number of subjects: 56
Study 22845008 — intervention group
Group type: COMPARATOR
Intervention: BAF312 non-titration regimen (10 mg starting dose)
Number of subjects: 56
Study 22845008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20975325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 145
Study 20975325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT-G)
Number of subjects: 145
Study 20975325 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment (either Sertraline or CBT-G)
Number of subjects: 145
Study 18296952 — intervention group
Group type: EXPERIMENTAL
Intervention: Static hamstring stretching (4 repetitions held for 45 seconds, 4 days per week)
Number of subjects: 21
Study 18296952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching intervention)
Number of subjects: 21
Study 17136940 — intervention group
Group type: EXPERIMENTAL
Intervention: RC+BD (high-intensity resistance and cardiovascular training and a balanced diet, 40% CHO: 40% PRO)
Number of subjects: 63
Study 17136940 — intervention group
Group type: COMPARATOR
Intervention: C+TD (moderate-intensity cardiovascular training and a traditional food guide pyramid diet, CHO 50 to 55%; PRO 15 to 20%; FAT < 30%)
Number of subjects: 63
Study 17136940 — intervention group
Group type: COMPARATOR
Intervention: C (inactive control group)
Number of subjects: 63
Study 12888778 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.1 mg/kg
Number of subjects: 60
Study 12888778 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 0.5 mg/kg
Number of subjects: 60
Study 12888778 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study 10730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus
Number of subjects: 1526
Study 10730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Shigella spp.
Number of subjects: 1526
Study 10730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Campylobacter spp.
Number of subjects: 1526
Study 10730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptosporidium parvum
Number of subjects: 1526
Study 10730034 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteropathogenic Escherichia coli
Number of subjects: 1526
Study 10730034 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with other complaints)
Number of subjects: 1526
Study 8967639 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HAV (IgG antibodies against hepatitis A virus)
Number of subjects: 411
Study 8967639 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBc (antibodies against hepatitis B virus core antigen)
Number of subjects: 411
Study 8967639 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV (antibodies against hepatitis C virus)
Number of subjects: 411
Study 8967639 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HEV (antibodies against hepatitis E virus)
Number of subjects: 411
Study 1547057 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 96
Study 1547057 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 96
Study 2932814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator (salbutamol 5 mg)
Number of subjects: 15
Study 2932814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator (ipratropium 1 mg)
Number of subjects: 15
Study 2932814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29808395 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with less depressed parents (N=51 for internalizing, N=38 for externalizing)
Number of subjects: 142
Study 29808395 — intervention group
Group type: COMPARATOR
Intervention: Children with more depressed parents (N=28 for internalizing, N=25 for externalizing)
Number of subjects: 142
Study 30481386 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 0
Study 30481386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26918314 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment for Class I malocclusions
Number of subjects: 66
Study 26918314 — intervention group
Group type: COMPARATOR
Intervention: Untreated Class I malocclusions (Control)
Number of subjects: 66
Study 24934787 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 3871
Study 24934787 — intervention group
Group type: COMPARATOR
Intervention: Single-agent paclitaxel (T)
Number of subjects: 3871
Study 22052216 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education on health belief model
Number of subjects: 130
Study 20214460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 15 microg BID
Number of subjects: 443
Study 20214460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 25 microg BID
Number of subjects: 443
Study 20214460 — intervention group
Group type: COMPARATOR
Intervention: Racemic formoterol 12 microg BID
Number of subjects: 443
Study 18512312 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐Asp (2500 IU/m2, intramuscularly once every two weeks for 4 weeks) in VDPAP regimen
Number of subjects: 135
Study 18512312 — intervention group
Group type: COMPARATOR
Intervention: L‐asparaginase (6000 IU/m2, three times a week for 2 weeks) in VDLP regimen
Number of subjects: 135
Study 15860170 — intervention group
Group type: EXPERIMENTAL
Intervention: Close lateral internal sphincterotomy
Number of subjects: 80
Study 15860170 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin (25 U injected into the internal sphincter)
Number of subjects: 80
Study 12436323 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy (n=13)
Number of subjects: 85
Study 12436323 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercutting decompression (n=27)
Number of subjects: 85
Study 12436323 — intervention group
Group type: COMPARATOR
Intervention: Control group (Laminectomy)
Number of subjects: 85
Study 10343464 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered PASI (SAPASI)
Number of subjects: 182
Study 8565513 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC C‐53
Number of subjects: 25
Study 8565513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula (LPM)
Number of subjects: 10
Study 1844007 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk based formula (LP)
Number of subjects: 10
Study 7075479 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine (Vivalan ICI)
Number of subjects: 88
Study 7075479 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 88
Study 7075479 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 88
Study 31176242 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept map-based teaching method
Number of subjects: 57
Study 31176242 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based teaching method
Number of subjects: 57
Study 28322416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive recruitment strategy (n=157)
Number of subjects: 320
Study 28322416 — intervention group
Group type: COMPARATOR
Intervention: Moderate recruitment strategy (n=163)
Number of subjects: 320
Study 28322416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive recruitment strategy
Number of subjects: 320
Study 28322416 — intervention group
Group type: COMPARATOR
Intervention: Moderate recruitment strategy
Number of subjects: 320
Study 25899896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2-g ginger rhizomes powder as two 1-g tablets per day)
Number of subjects: 80
Study 25899896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch with the same amount)
Number of subjects: 80
Study 23344545 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (lopinavir/ritonavir/zidovudine/lamivudine or abacavir/zidovudine/lamivudine)
Number of subjects: 730
Study 21215809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous busulfan (3.2 mg/kg/day)
Number of subjects: 58
Study 19196357 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein plan (HP)
Number of subjects: 75
Study 19196357 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced conventional plan (C)
Number of subjects: 75
Study 16774505 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint (SS)
Number of subjects: 16
Study 16774505 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal splint (PS)
Number of subjects: 16
Study 16774505 — intervention group
Group type: COMPARATOR
Intervention: Both splints (SS and PS)
Number of subjects: 16
Study 15504987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (4 x 40 IU/day)
Number of subjects: 40
Study 15504987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11564552 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-cyclodextrin artemisinin complex
Number of subjects: 12
Study 11564552 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-cyclodextrin artemisinin complex
Number of subjects: 12
Study 11564552 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin 250 (control)
Number of subjects: 12
Study 9104876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretraining at 65% VO2peak
Number of subjects: 19
Study 9104876 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining at same absolute workload
Number of subjects: 19
Study 9104876 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining at same relative workload
Number of subjects: 19
Study 8217224 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐stat protocol
Number of subjects: 70
Study 8217224 — intervention group
Group type: COMPARATOR
Intervention: alpha‐stat protocol
Number of subjects: 70
Study 3315535 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole 900 mg/day
Number of subjects: 47
Study 3315535 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole 1350 mg/day
Number of subjects: 47
Study 3315535 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaprazole
Number of subjects: 47
Study 28902035 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-particle hyaluronic acid (SPHA) injectable gel
Number of subjects: 25
Study 28918408 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 0
Study 28918408 — intervention group
Group type: COMPARATOR
Intervention: Implementation of PDA
Number of subjects: 0
Study 26248362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ)
Number of subjects: 0
Study 23984051 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270
Study 23984051 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270
Study 23984051 — intervention group
Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (placebo group)
Number of subjects: 270
Study 21389332 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose at 2 kcal/min (G2)
Number of subjects: 12
Study 21389332 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose at 3 kcal/min (G3)
Number of subjects: 12
Study 21389332 — intervention group
Group type: COMPARATOR
Intervention: Glucose at 1 kcal/min (G1)
Number of subjects: 12
Study 21389332 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 12
Study 18312040 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy (patient-centered strategy to identify and overcome barriers to adherence)
Number of subjects: 349
Study 18312040 — intervention group
Group type: COMPARATOR
Intervention: Basic guideline implementation strategy (usual VA procedures)
Number of subjects: 349
Study 18312040 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation strategy
Number of subjects: 349
Study 16546673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic SPECT imaging
Number of subjects: 12
Study 16546673 — intervention group
Group type: COMPARATOR
Intervention: Whole-body distribution imaging
Number of subjects: 12
Study 16546673 — intervention group
Group type: COMPARATOR
Intervention: Brain SPECT imaging
Number of subjects: 12
Study 15156935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract (2 g daily for 6 months)
Number of subjects: 48
Study 15156935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11448368 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 24
Study 11448368 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 24
Study 11448368 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 9729672 — intervention group
Group type: EXPERIMENTAL
Intervention: Strafill NG2 amalgam alloy
Number of subjects: 81
Study 9729672 — intervention group
Group type: COMPARATOR
Intervention: googfill 700 amalgam alloy
Number of subjects: 81
Study 7983122 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 52
Study 7983122 — intervention group
Group type: COMPARATOR
Intervention: Patellar retention
Number of subjects: 52
Study 7983122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study 3292005 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal incision (SI)
Number of subjects: 0
Study 3292005 — intervention group
Group type: COMPARATOR
Intervention: Midline incision (C)
Number of subjects: 0
Study 31749961 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on control of antimicrobial resistance
Number of subjects: 8716
Study 31749961 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in a university hospital
Number of subjects: 8716
Study 31749961 — intervention group
Group type: EXPERIMENTAL
Intervention: Age classes 26-35 years
Number of subjects: 8716
Study 31749961 — intervention group
Group type: EXPERIMENTAL
Intervention: Age classes 36-45 years
Number of subjects: 8716
Study 31749961 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical professional status
Number of subjects: 8716
Study 31749961 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in an intensive care unit
Number of subjects: 8716
Study 28374849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks
Number of subjects: 4629
Study 28374849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks
Number of subjects: 4629
Study 28374849 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo/ezetimibe)
Number of subjects: 4629
Study 28374849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4629
Study 26749730 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapectineal buttress reconstruction plate (group A)
Number of subjects: 8
Study 26749730 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapectineal buttress locking reconstruction plate (group B)
Number of subjects: 8
Study 26749730 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction plate combined with trans‐plate quadrilateral screws (group C)
Number of subjects: 8
Study 26749730 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior reconstruction plate‐lag screw (group D)
Number of subjects: 8
Study 26749730 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C, D)
Number of subjects: 8
Study 23276892 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PTCD with bile re‐infusion (n = 56)
Number of subjects: 116
Study 23276892 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment alone (n = 60)
Number of subjects: 116
Study 21607782 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump stress condition
Number of subjects: 61
Study 21607782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 18427774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 40
Study 18427774 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 40
Study 16828301 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermic cardiopulmonary bypass (CPB) at 31 degrees C
Number of subjects: 30
Study 16828301 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermic cardiopulmonary bypass (CPB) at 32 degrees C
Number of subjects: 30
Study 16828301 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall postoperative mechanical ventilatory support
Number of subjects: 30
Study 16828301 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ICU stay
Number of subjects: 30
Study 16828301 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hemodynamic improvement
Number of subjects: 30